Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs to the treatment of various cancers. The company is also involved in the production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. Burzynski Research Institute, Inc. was incorporated in 1984 and is headquartered in Houston, Texas.